Tardive dyskinesia is a persistent, often irreversible involuntary movement disorder caused by prolonged exposure to dopamine receptor blocking agents (DRBAs), most commonly antipsychotics and metoclopramide. [1-2] Unlike acute dystonia or akathisia, TD develops insidiously after months to years of DRBA exposure and is characterized by repetitive, stereotyped orofacial movements (lip smacking, tongue protrusion, chewing) with possible limb and truncal involvement. [1-2] The critical ED pearl is distinguishing TD from other drug-induced movement disorders, as anticholinergics (benztropine) worsen TD but treat drug-induced parkinsonism — the treatments are essentially opposite. [1][3]
1. History
- Medication exposure: Identify all current and prior DRBAs — antipsychotics (haloperidol, risperidone, olanzapine, quetiapine, aripiprazole), antiemetics (metoclopramide, prochlorperazine, promethazine) [1-2]
- Duration of DRBA use: Requires ≥3 months of exposure (≥1 month if age ≥60) [1]
- Onset timing: Insidious onset during treatment or within 4 weeks of oral DRBA discontinuation (8 weeks for long-acting injectables) [1]
- Movement characterization: Involuntary, repetitive — lip smacking, tongue protrusion, chewing, grimacing, finger/toe movements, trunk rocking [1-2]
- Symptom modifiers: Worsened by stress, stimulants, anticholinergics; reduced by relaxation, voluntary movements of affected body parts; absent during sleep [1]
- Recent medication changes: Dose reduction or discontinuation of antipsychotic can transiently worsen TD movements [3]
- Functional impact: Difficulty eating, swallowing, speaking, social avoidance, depression [1]
2. Alarm Features
- Respiratory dyskinesia: Diaphragmatic/pharyngeal involvement causing irregular breathing — rare but potentially life-threatening [1-2]
- Severe dysphagia with aspiration risk or inability to maintain oral intake [1]
- Significant weight loss from impaired eating mechanics [1]
- Suicidal ideation — severe TD is associated with depression and suicidality [1]
- Oral self-mutilation: Tongue/cheek ulceration, tooth loss, macroglossia [1]
- Neuroleptic malignant syndrome (NMS): Hyperthermia, rigidity, altered mental status, autonomic instability — can co-occur with DRBA use and must be ruled out [4]
- New focal neurological signs suggesting an alternative etiology (Huntington's, Wilson's, stroke) [1]
3. Medications
Causative agents (DRBAs):
- First-generation antipsychotics (haloperidol, chlorpromazine) — highest risk [5]
- Second-generation antipsychotics (risperidone, olanzapine, aripiprazole, quetiapine) — lower but still significant risk; annualized incidence ~3.9% vs 5.5% for FGAs [5]
- Antiemetics: metoclopramide, prochlorperazine, promethazine
- Rarely: SSRIs (almost never without concurrent/prior DRBA exposure) [6]
FDA-approved treatments (VMAT2 inhibitors):
- Valbenazine (Ingrezza): 40 mg PO daily × 1 week, then 80 mg daily (40 mg for hepatic impairment or CYP2D6 poor metabolizers) [4]
- Deutetrabenazine (Austedo): Start 6 mg PO BID, titrate weekly by 6 mg/day to max 24 mg BID (take with food) [2][7]
Adjunctive/second-line:
- Clonazepam: Probably effective short-term (Level B, AAN); useful for acute symptomatic relief but efficacy wanes after ~3–5 months [8]
- Amantadine, tetrabenazine: Level C evidence [9]
Medications to AVOID in TD:
- Anticholinergics (benztropine, trihexyphenidyl) — worsen TD [1][3][10]
- Increasing the antipsychotic dose — may temporarily mask symptoms but worsens long-term prognosis [1]
Key drug interactions for VMAT2 inhibitors:
- Valbenazine: CYP3A4 and CYP2D6 interactions; avoid strong CYP3A4 inducers [11]
- Deutetrabenazine: CYP2D6 interactions; contraindicated in hepatic impairment [11]
- Both carry warnings for QT prolongation — avoid in congenital long QT syndrome [4]
4. Diet
- No specific dietary triggers for TD
- Assess for malnutrition/weight loss secondary to orofacial dyskinesia impairing chewing and swallowing [1]
- Deutetrabenazine must be taken with food for adequate absorption [11]
- Consider soft/pureed diet if significant orofacial involvement impairs safe oral intake
5. Review of Systems
- Neurological: Involuntary movements (face, tongue, jaw, limbs, trunk), difficulty speaking, swallowing, breathing [1-2]
- Psychiatric: Depression, anxiety, social withdrawal, suicidal ideation (TD itself and as VMAT2 inhibitor side effect) [1-2]
- GI: Dysphagia, drooling, weight loss, oral ulceration [1]
- Respiratory: Irregular breathing pattern (respiratory dyskinesia) [2]
- Musculoskeletal: Gait disturbance from truncal/limb involvement [1]
6. Collateral History and Family History
- Collateral from caregivers/family: Often first to notice movements; patients may have limited awareness [12]
- Psychiatric treatment history: Full medication timeline including all prior antipsychotics, doses, and durations
- Family history: Huntington's disease, Wilson's disease, other hereditary choreas — essential to exclude genetic mimics [1]
- Social context: Institutionalized patients have higher TD prevalence; assess impact on social functioning and employment [1]
7. Risk Factors
- Age — most important risk factor; elderly (especially >55) have incidence up to 25–30% after 1 year of DRBA exposure [1]
- Cumulative DRBA exposure — dose and duration [1]
- First-generation antipsychotic use (prevalence 32% vs 13% with SGAs) [5]
- Early extrapyramidal side effects (drug-induced parkinsonism predicts later TD) [3][5]
- Postmenopausal women [1]
- Mood disorders (especially major depressive disorder) [1]
- Substance use disorders (alcohol use disorder) [1]
- Neurological comorbidities, diabetes, cognitive impairment [13]
8. Differential Diagnosis
This is the most critical section for ED management — misdiagnosis leads to harmful treatment: [1][14]
- Drug-induced parkinsonism (DIP): Hypokinetic (bradykinesia, rigidity, resting tremor 3–6 Hz) — treated with anticholinergics, which worsen TD [1][3]
- Acute dystonia: Onset within hours to days of DRBA initiation; sustained posturing — treat with diphenhydramine/benztropine [2]
- Acute/subacute akathisia: Inner restlessness with inability to sit still; onset within days to weeks [2]
- Withdrawal dyskinesia: Emerges upon DRBA discontinuation; resolves within 4 weeks (if persists >4 weeks → TD) [1]
- Huntington's disease: Chorea + cognitive decline + family history; genetic testing [1]
- Wilson's disease: Young patient, Kayser-Fleischer rings, hepatic disease; ceruloplasmin [1]
- Sydenham's chorea: Post-streptococcal, pediatric [1]
- Spontaneous/senile dyskinesia: Occurs in >5% of elderly without DRBA exposure [1]
- Thyrotoxicosis, SLE, heavy metal poisoning [1]
- Ill-fitting dentures mimicking orofacial movements [1]
9. Past Medical History
- Psychiatric diagnoses: Schizophrenia, schizoaffective disorder, bipolar disorder, MDD — both as indication for DRBAs and as independent risk factor [1]
- Prior movement disorder episodes: Previous EPS, acute dystonic reactions [5]
- Chronic medical conditions: Diabetes (increased risk), hepatic impairment (affects VMAT2 inhibitor dosing) [4][13]
- Dental history: Edentulous patients may have spontaneous orofacial movements [1]
10. Physical Exam
Focused neurological/movement exam:
- Orofacial: Observe at rest for lip smacking, tongue protrusion, lateral jaw movements, puckering, chewing — ask patient to open mouth and observe tongue [1-2]
- Extremities: Choreiform or athetoid finger/toe movements, piano-playing movements of fingers [1]
- Trunk: Rocking, pelvic thrusting, shoulder shrugging [2]
- Activation maneuvers: Have patient perform rapid alternating movements of contralateral limb — may unmask subtle dyskinesia [1]
- Gait: Assess for truncal instability
Distinguish from parkinsonism:
- TD = hyperkinetic (involuntary excess movement); DIP = hypokinetic (bradykinesia, rigidity, resting tremor) [3]
- TD movements are irregular, non-rhythmic; parkinsonian tremor is rhythmic 3–6 Hz [1]
Vital signs: Assess for NMS (fever, tachycardia, labile BP) [4]
11. Lab Studies
- No specific labs diagnose TD — diagnosis is clinical
- Labs to rule out mimics:
- TSH (thyrotoxicosis)
- Ceruloplasmin, serum copper (Wilson's disease — if age <50 with new dyskinesia)
- ANA (SLE)
- CMP (hepatic/metabolic derangement; baseline before VMAT2 inhibitor)
- Heavy metals if exposure history
- CK if concern for NMS
- Pregnancy test in women of childbearing age before initiating treatment
12. Imaging
- Not routinely indicated if clinical presentation is classic TD with clear DRBA exposure history
- Brain MRI: Consider if atypical features, focal neurological signs, young age without DRBA exposure, or concern for structural lesion (Huntington's caudate atrophy, Wilson's basal ganglia changes) [1]
- CT head: Only if acute presentation raises concern for stroke or mass
13. Special Tests
- Abnormal Involuntary Movement Scale (AIMS): The standard structured assessment tool for TD severity; 12-item scale rating movements in 7 body regions plus global severity, incapacitation, and dental status. Should be performed at baseline and serially to monitor treatment response. [12][15]
- Schooler-Kane criteria: Diagnostic criteria requiring ≥3 months DRBA exposure, moderate movements in ≥1 body area or mild in ≥2 areas [8]
- Video documentation: Record movements for comparison and specialist consultation [14]
- Genetic testing: Huntington's gene (HTT CAG repeats) if family history or clinical suspicion [1]
14. ECG
- Obtain baseline ECG before initiating VMAT2 inhibitors — both valbenazine and deutetrabenazine can prolong QT interval [4]
- Contraindicated in congenital long QT syndrome [4]
- Assess QT interval before dose escalation in patients at increased risk (electrolyte abnormalities, concomitant QT-prolonging medications) [4]
- Rule out arrhythmia if autonomic instability is present (NMS concern)
15. Assessment
Severity stratification:
- Mild: Orofacial movements only, minimal functional impact — may be managed with observation and outpatient referral
- Moderate: Orofacial + limb involvement, social impairment, difficulty eating — warrants VMAT2 inhibitor initiation [15]
- Severe: Generalized movements, dysphagia, respiratory involvement, weight loss, self-injury, suicidality — urgent treatment and possible admission [1]
Key clinical pearls:
- TD is often irreversible — the risk of permanence increases with delayed recognition [12][15]
- Movements may transiently worsen with DRBA dose reduction or discontinuation [3]
- TD can coexist with other drug-induced movement disorders (parkinsonism, tremor) in the same patient [14]
- Increasing the antipsychotic dose may temporarily suppress movements but worsens long-term outcome [1]
16. Treatment Plan
Step 1 — Immediate ED management:
- Do NOT give anticholinergics (benztropine, trihexyphenidyl) — these worsen TD [1][10]
- Do NOT abruptly discontinue the antipsychotic — can worsen movements acutely and destabilize psychiatric illness [3][16]
- For acute symptomatic distress: Clonazepam 0.5–2 mg PO/IV may provide short-term relief (Level B evidence, AAN) [8]
Step 2 — Medication optimization (coordinate with psychiatry):
- Consider dose reduction of the offending DRBA to the minimum effective dose [17]
- Consider switching to a lower-risk antipsychotic: clozapine or quetiapine [5][17]
- Discontinue non-essential DRBAs (e.g., metoclopramide) [10]
Step 3 — Definitive treatment (VMAT2 inhibitors):
- Valbenazine: 40 mg PO daily → 80 mg daily after 1 week [4]
- Deutetrabenazine: 6 mg PO BID → titrate by 6 mg/day weekly, max 48 mg/day (24 mg BID); take with food [2][7]
- Both are Level A evidence (AAN) and APA-recommended for moderate-to-severe TD [9][15]
- AIMS response rates (≥50% improvement): 33–50% [7]
- TD symptoms recur within ~4 weeks of VMAT2 inhibitor discontinuation — ongoing treatment is typically required [2]
Adjunctive options:
- Clonazepam for short-term use (Level B) — efficacy wanes after 3–5 months [8]
- Ginkgo biloba (Level B), amantadine (Level C) [9]
- Botulinum toxin for focal tardive dystonia [18]
17. Disposition
Admit if:
- Respiratory dyskinesia with airway compromise
- Severe dysphagia with aspiration risk or inability to maintain oral intake
- Suicidal ideation or severe psychiatric decompensation
- Concern for NMS (fever, rigidity, altered mental status, autonomic instability)
- Need for urgent psychiatric medication adjustment in unstable patient
Discharge if:
- Mild-to-moderate TD without airway, swallowing, or safety concerns
- Stable psychiatric status
- Able to follow up with psychiatry and/or neurology within 1–2 weeks
- Appropriate return precautions understood
Consult triggers:
- Psychiatry: All cases — for medication adjustment and VMAT2 inhibitor initiation
- Neurology/Movement disorders: Diagnostic uncertainty, severe/refractory TD, consideration of botulinum toxin or DBS [9][18]
18. Follow Up / Return Precautions
Follow-up timing:
- Psychiatry within 1–2 weeks for medication review and VMAT2 inhibitor initiation/titration
- Serial AIMS assessments at baseline and every visit to track treatment response [12][15]
- If VMAT2 inhibitor started: reassess at 2–4 weeks for dose titration and side effects
Return precautions — instruct patient/caregiver to return for:
- Difficulty breathing or swallowing
- Inability to eat or drink
- Worsening involuntary movements despite treatment
- Fever, severe muscle stiffness, confusion (NMS)
- New depression, suicidal thoughts (VMAT2 inhibitor side effect) [2]
- Falls or injuries related to movement disorder
Patient counseling:
- TD may be irreversible but can improve with treatment — early intervention is critical [12][15]
- Do NOT stop psychiatric medications abruptly without physician guidance [3]
- Avoid anticholinergic medications (OTC included) [10]
- VMAT2 inhibitors require ongoing use; symptoms typically return if stopped [2]
References
1. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
2. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
3. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
4. Recent Developments in Drug-Induced Movement Disorders: A Mixed Picture. — Factor SA, Burkhard PR, Caroff S, et al. The Lancet. Neurology. 2019.
5. Recent Developments in Drug-Induced Movement Disorders: A Mixed Picture. — Factor SA, Burkhard PR, Caroff S, et al. The Lancet. Neurology. 2019.
6. How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. — Stahl SM, Sy S, Maguire GA. Acta Psychiatrica Scandinavica. 2021.
7. How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. — Stahl SM, Sy S, Maguire GA. Acta Psychiatrica Scandinavica. 2021.
8. FDA Drug Label. — Updated date: 2026-04-17. Food and Drug Administration.
9. FDA Drug Label. — Updated date: 2026-04-17. Food and Drug Administration.
10. Schizophrenia. — Marder SR, Cannon TD. The New England Journal of Medicine. 2019.
11. Schizophrenia. — Marder SR, Cannon TD. The New England Journal of Medicine. 2019.
12. Movement Disorders Induced by Psychiatric Drugs That Do Not Block Dopamine Receptors. — Friedman JH. Parkinsonism & Related Disorders. 2020.
13. Movement Disorders Induced by Psychiatric Drugs That Do Not Block Dopamine Receptors. — Friedman JH. Parkinsonism & Related Disorders. 2020.
14. Valbenazine and Deutetrabenazine: Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia. — Khorassani F, Luther K, Talreja O. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists. 2020.
15. Valbenazine and Deutetrabenazine: Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia. — Khorassani F, Luther K, Talreja O. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists. 2020.
16. Evidence-Based Guideline: Treatment of Tardive Syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. — Bhidayasiri R, Fahn S, Weiner WJ, et al. Neurology. 2013.
17. Evidence-Based Guideline: Treatment of Tardive Syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. — Bhidayasiri R, Fahn S, Weiner WJ, et al. Neurology. 2013.
18. Updating the Recommendations for Treatment of Tardive Syndromes: A Systematic Review of New Evidence and Practical Treatment Algorithm. — Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Journal of the Neurological Sciences. 2018.
19. Updating the Recommendations for Treatment of Tardive Syndromes: A Systematic Review of New Evidence and Practical Treatment Algorithm. — Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Journal of the Neurological Sciences. 2018.
20. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®. — Steinman MA. Journal of the American Geriatrics Society. 2025.
21. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®. — Steinman MA. Journal of the American Geriatrics Society. 2025.
22. Tardive Dyskinesia: Placing Vesicular Monoamine Transporter Type 2 (VMAT2) Inhibitors Into Clinical Perspective. — Citrome L. Expert Review of Neurotherapeutics. 2018.
23. Tardive Dyskinesia: Placing Vesicular Monoamine Transporter Type 2 (VMAT2) Inhibitors Into Clinical Perspective. — Citrome L. Expert Review of Neurotherapeutics. 2018.
24. Diagnostic and Treatment Fundamentals for Tardive Dyskinesia. — Correll CU, Citrome L. The Journal of Clinical Psychiatry. 2021.
25. Diagnostic and Treatment Fundamentals for Tardive Dyskinesia. — Correll CU, Citrome L. The Journal of Clinical Psychiatry. 2021.
26. From Assessment to Intervention: Evidence-Based Approaches in Tardive Dyskinesia. — Matthews D. CNS Spectrums. 2025.
27. From Assessment to Intervention: Evidence-Based Approaches in Tardive Dyskinesia. — Matthews D. CNS Spectrums. 2025.
28. Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice. — Hauser RA, Meyer JM, Factor SA, et al. CNS Spectrums. 2022.
29. Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice. — Hauser RA, Meyer JM, Factor SA, et al. CNS Spectrums. 2022.
30. Measurement-Based Diagnosis and Treatment for Tardive Dyskinesia. — Correll CU, Citrome L. The Journal of Clinical Psychiatry. 2021.
31. Measurement-Based Diagnosis and Treatment for Tardive Dyskinesia. — Correll CU, Citrome L. The Journal of Clinical Psychiatry. 2021.
32. Efficacy and Acceptability of Pharmacological Interventions for Tardive Dyskinesia in People With Schizophrenia or Mood Disorders: A Systematic Review and Network Meta-Analysis. — Solmi M, Fornaro M, Caiolo S, et al. Molecular Psychiatry. 2025.
33. Efficacy and Acceptability of Pharmacological Interventions for Tardive Dyskinesia in People With Schizophrenia or Mood Disorders: A Systematic Review and Network Meta-Analysis. — Solmi M, Fornaro M, Caiolo S, et al. Molecular Psychiatry. 2025.
34. Treatment Recommendations for Tardive Dyskinesia. — Ricciardi L, Pringsheim T, Barnes TRE, et al. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2019.
35. Treatment Recommendations for Tardive Dyskinesia. — Ricciardi L, Pringsheim T, Barnes TRE, et al. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2019.
36. Treatment of Tardive Dyskinesia: A General Overview With Focus on the Vesicular Monoamine Transporter 2 Inhibitors. — Niemann N, Jankovic J. Drugs. 2018.
37. Treatment of Tardive Dyskinesia: A General Overview With Focus on the Vesicular Monoamine Transporter 2 Inhibitors. — Niemann N, Jankovic J. Drugs. 2018.